₹194 Cr
--
₹-9 Cr
As on 13-Aug-2024 IST
₹-2.01
•
-1.60%
₹125.50
₹126.85
₹127.87
₹117.00
1,67,120
₹90.80 - 132.45
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Mangalam Drugs
| 25.82 | 15.86 | 28.70 | 16.55 | -8.11 | 28.98 | 53.78 |
|
BSE Healthcare
| 30.05 | 6.86 | 18.26 | 46.79 | 16.31 | 26.45 | 12.81 |
|
BSE Small Cap
| 24.81 | -1.39 | 17.32 | 50.92 | 26.42 | 33.21 | 18.27 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Mangalam Drugs
| -28.44 | 5.42 | -5.90 | 388.37 | -61.78 | -65.04 | 63.71 |
|
BSE Small Cap
| 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 | 59.64 |
|
BSE Healthcare
| 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 | 0.49 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Mangalam Drugs And Organics Ltd stood at ₹ 357 Cr as on 31-Mar-24
The share price of Mangalam Drugs And Organics Ltd is ₹123.49 (NSE) and ₹122.55 (BSE) as of 13-Aug-2024 IST. Mangalam Drugs And Organics Ltd has given a return of -8.11% in the last 3 years.
Mangalam Drugs And Organics Ltd has a market capitalisation of ₹ 194 Cr as on 13-Aug-2024. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Mangalam Drugs And Organics Ltd is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Mangalam Drugs And Organics Ltd and enter the required number of quantities and click on buy to purchase the shares of Mangalam Drugs And Organics Ltd.
Mangalam Drugs & Organics Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. It offers a range of API products, which include Acyclovir, Amodiaquine, Artemether, Artesunate, Atazanavir Sulfate, Bisoprolol Fumarate, Chloroquine Phosphate, Dihydroartemisinin, and Dolutegravir Sodium; Efavirenz, Emtricitabine, Furosemide, Hydroxychloroquine Sulphate, Lumefantrine, and Nimesulide; Nitrofurantoin Anhydrous and Monohydrate; Primaquine and Piperaquine Phosphate; Pregabalin, Pyrimethamine, Pyronaridine Tetraphosphate, and Sulfadoxine; and Tenofovir Alafenamide Hemifumarate and Disoproxil Fumarate. The company also offers intermediates comprising 2-Dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-Dichloro-5-methoxy pyrimidine; 4,7 Dichloroquinoline; Ortho phenoxy methane sulfonanilide; and Tenofovir Alafenamide Base and Disoproxil Base. In addition, it offers specialty chemicals, such as Menthol; 2,3-Dihydrophthalazine-1, 4-dione; and 4-cynoethyl-2-methyl phenol. Further, the company's products under development include Tafenoquine Succinate, Bictegravir Na, Favipiravir, and Molnupiravir; and Elvitegravir, Cobicistat, Daclatasvir dihydrochloride, Ledipasvir, and Velpatasvir. The company was incorporated in 1972 and is based in Mumbai, India.
The prominent promoters of Mangalam Drugs And Organics Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
SHRI JB PHARMA PRIVATE LIMITED |
16.74%
|
|
SHREE KISHORIJU TRADING AND INVESTMENTS PRIVATE LIMITED |
6.94%
|
|
SHREE RASBIHARI TRADING AND INVESTMENTS PRIVATE LIMITED |
6.39%
|
|
Dhoot Govardhan Murlidhar |
3.23%
|
|
Dhoot Brijmohan Murlidhar |
3.08%
|
The chairman of the company is Govardhan M Dhoot, and the managing director is Govardhan M Dhoot.
The promoters of Mangalam Drugs And Organics Ltd have pledged 7.49% of the total equity as on Jun-24.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
7,101
|
|
|
5,403
|
|
|
5,284
|
|
|
3,950
|
| Mangalam Drugs And Organics Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
-6.43
|
|
Operating margin(%)
|
0.75
|
|
Net Margin(%)
|
-2.45
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Mangalam Drugs And Organics Ltd was ₹-9 Cr.
₹193.98 Cr
₹368.60 Cr
₹-9.05 Cr
₹1.01 Cr
₹74.59 Cr
50.32%
High
₹90.80 - 132.45
₹10.00
1,58,28,248
NSE: MANGALAM, BSE: 532637
Mumbai, Maharashtra
www.mangalamdrugs.com
Mangalam Drugs & Organics Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. It offers a range of API products, which include Acyclovir, Amodiaquine, Artemether, Artesunate, Atazanavir Sulfate,... Bisoprolol Fumarate, Chloroquine Phosphate, Dihydroartemisinin, and Dolutegravir Sodium; Efavirenz, Emtricitabine, Furosemide, Hydroxychloroquine Sulphate, Lumefantrine, and Nimesulide; Nitrofurantoin Anhydrous and Monohydrate; Primaquine and Piperaquine Phosphate; Pregabalin, Pyrimethamine, Pyronaridine Tetraphosphate, and Sulfadoxine; and Tenofovir Alafenamide Hemifumarate and Disoproxil Fumarate. The company also offers intermediates comprising 2-Dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-Dichloro-5-methoxy pyrimidine; 4,7 Dichloroquinoline; Ortho phenoxy methane sulfonanilide; and Tenofovir Alafenamide Base and Disoproxil Base. In addition, it offers specialty chemicals, such as Menthol; 2,3-Dihydrophthalazine-1, 4-dione; and 4-cynoethyl-2-methyl phenol. Further, the company's products under development include Tafenoquine Succinate, Bictegravir Na, Favipiravir, and Molnupiravir; and Elvitegravir, Cobicistat, Daclatasvir dihydrochloride, Ledipasvir, and Velpatasvir. The company was incorporated in 1972 and is based in Mumbai, India. Read more
Stocks 
Mangalam Drugs And Organics Ltd.
Widely used:
